Cytotoxic T Lymphocyte Density and PD‐L1 Expression Predict the Response to Anti‐PD1 Therapy in Recurrent Oral Squamous Cell Carcinoma
Microbiology and Immunology · 2025
DOI: 10.1111/1348-0421.13220 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology and Immunology, 2025. Verfasst von Mayuko Yamashita und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: B7-H1 Antigen, Mouth Neoplasms, Programmed Cell Death 1 Receptor, T-Lymphocytes, Cytotoxic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 20H03459)., Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Oral squamous cell carcinoma (OSCC) is one of the most common head and neck cancers, and immunotherapy targeting programmed cell death 1 (PD‐1) has become a treatment option for recurrent OSCC after surgery and radiation therapy. However, few studies have identified definitive biomarkers for predicting patient response to anti‐PD1 therapy in OSCC. In the present study, biopsy specimens were obtained from 23 patients with recurrent OSCC who were subsequently treated with anti‐PD1 therapy. Immunohistochemical examinations of CD3, CD8, FOXP3, CD103, CD163, programmed cell death ligand 1 (PD‐L1), HLA‐A/B/C, HLA‐DR, and β2 microglobulin were performed, and their correlation with clinical response was statistically analyzed. We found that an increased density of CD8‐positive lymphocytes and increased PD‐L1 expression predicted a favorable response to anti‐PD1 therapy in recurrent OSCC. In contrast, clinical factors such as age and sex, and immune‐related factors such as HLA‐Classes I and II, were not associated with the response to anti‐PD1 therapy. Taken together, our results suggest that immunohistochemical analysis of CD8 and PD‐L1 may be useful for predicting the efficacy of anti‐PD1 therapy in recurrent OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Oral & Maxillofacial Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Tumor Pathology, Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan.
Förderung
- This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology of Japan (No. 20H03459).
- Japan Society for the Promotion of Science
Zitieren
APA
Yamashita, M., Yano, H., Komohara, Y., Yamada, R., Fujiwara, Y., Hirayama, M., Seki, Y., Yoshida, R., & Nakayama, H. (2025). Cytotoxic T Lymphocyte Density and PD‐L1 Expression Predict the Response to Anti‐PD1 Therapy in Recurrent Oral Squamous Cell Carcinoma. Microbiology and Immunology. https://doi.org/10.1111/1348-0421.13220
Vancouver
Yamashita M, Yano H, Komohara Y, Yamada R, Fujiwara Y, Hirayama M, et al. Cytotoxic T Lymphocyte Density and PD‐L1 Expression Predict the Response to Anti‐PD1 Therapy in Recurrent Oral Squamous Cell Carcinoma. Microbiology and Immunology. 2025. doi:10.1111/1348-0421.13220
BibTeX
@article{Yamashita2025,
author = {Yamashita, Mayuko and Yano, Hiromu and Komohara, Yoshihiro and Yamada, Rin and Fujiwara, Yukio and Hirayama, Masatoshi and Seki, Yuki and Yoshida, Ryoji and Nakayama, Hideki},
title = {Cytotoxic T Lymphocyte Density and PD‐L1 Expression Predict the Response to Anti‐PD1 Therapy in Recurrent Oral Squamous Cell Carcinoma},
journal = {Microbiology and Immunology},
year = {2025},
doi = {10.1111/1348-0421.13220}
}
EUVIMED